Search

Displaying results 6121 - 6130 of 10000 in total
  1. Drug

    ARG201

    go.drugbank.com/drugs/DB06621
    Experimental

    ARG201, a bovine-derived Type I collagen, aims to induce immune tolerance in patients with Diffuse Systemic Scleroderma (dcSSc). … This drug was investigated in the completed clinical trial NCT0000567 (Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma)

  2. Drug

    Vipadenant

    go.drugbank.com/drugs/DB06625
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  3. Drug

    Zibotentan

    go.drugbank.com/drugs/DB06629
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients.

    Synonyms: 4-AP, 4-AminopyridineCategories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates
  6. Drug

    DiaPep 277

    go.drugbank.com/drugs/DB06651
    Investigational

    DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).

    Categories: Group I Chaperonins, Diabetes Mellitus, Type 1
  7. Drug

    Saredutant

    go.drugbank.com/drugs/DB06660
    Investigational

    Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

    Categories: Heterocyclic Compounds, 1-Ring, Receptors, Neurokinin-2, antagonists & inhibitors
  8. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Gimatecan

    go.drugbank.com/drugs/DB06721
    Investigational

    Gimatecan is an orally available 7-t-butoxyiminomethyl-substituted lipophilic camptothecin derivative.

    Synonyms: (4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3',4':6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime, (4S)-11-[(E)-(tert-butoxyimino)methyl]-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
  10. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    It is a more commonly prescribed drug in Europe. … It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670].

    Synonyms: 2-[(2',6'-dichlorophenyl)amino]phenylacetoxyacetic acid, 2-[(2,6-dichlorophenyl)amino]phenylacetoxyacetic acidMixtures: ZERODOL P